Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Sirolimus in Patients With Active Systemic Lupus Erythematosus Despite Standard of Care: a Multi-center, Double Blinded, Randomized, Placebo-controlled, Phase 3 Trial

NCT04582136 is registered in ClinicalTrials.gov with Chinese SLE Treatment And Research Group as lead sponsor.

NCT NCT04582136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Sirolimus in Patients With Active Systemic Lupus Erythematosus Despite Standard of Care: a Multi-center, Double Blinded, Randomized, Placebo-controlled, Phase 3 Trial
Lead sponsor
Chinese SLE Treatment And Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 4, 2021
Completion date
January 31, 2026
Enrollment
146 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus